Jim Cramer, the class clowns "The Street" has "upgraded" GHDX.The last line in the rating is the hook. Good Luck
NEW YORK (TheStreet) -- Genomic Health (Nasdaq:GHDX) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.